Eli Lilly and Company consolidates market position with weight loss drugs

During the Covid pandemic, we saw pharmaceutical companies effectively capitalizing on vaccines. Eli Lilly and Company is one of the companies whose business did not stop even during the lockdowns, despite the fact that it does not have its own vaccine against Covid-19. It is developing drugs that are linked to the treatment of this disease. In addition, it wants to strengthen its position in the market through weight-loss aids. In this respect, it has already announced that it has entered into an acquisition agreement with Versanis. In addition, it is also looking to acquire DICE Therapeutics.

It has been active on the market since 1876

The American pharmaceutical corporation Eli Lilly and Company, headquartered in Indianapolis, operates in 18 countries and its products are distributed in approximately 125 countries. The company is known for its drugs for depression, but its primary source of revenue is diabetes drugs. Its pioneering achievements include the mass production of a polio vaccine, for example. Most recently, through its acquisition with Versanis, it will gain access to an experimental drug for obesity, which has become a significant problem in the world. In the US alone, more than two-thirds of the population is obese.

Acquisition for USD 1.93 billion

Eli Lilly and Company has entered into a definitive agreement to acquire Versanis, a privately held biotechnology firm, to strengthen its market presence in the obesity treatment space. Versanis is known for its experimental drug bimagrumab, which it licensed from Swiss pharmaceutical company Novartis. This like differs from competing products in that it directly targets fat cells without suppressing appetite or causing muscle loss. As Eli Lilly is working on more weight loss products, through Versanis, it might be able to effectively cement its place among the leading manufacturers of this kind of products.

Eli Lilly is also about to acquire DICE

Eli Lilly and Company also announced the extension of the expiration date of its tender offer to acquire all of the common stock of DICE Therapeutics, Inc. for an aggregate purchase price of $48 per share.* The initial expiration date, set to expire on July 28, 2023, has been extended to August 8, 2023, unless extended or terminated earlier. The acquisition of the company is expected to close in Q3 2023, subject to standard closing conditions, including an antitrust review and tender of a majority of the outstanding shares. As of July 24, 2023, approximately 9,581,902 shares have been tendered, representing 20.05 percent of the issued and outstanding shares. The shares tendered in the previous tender offer do not require a re-tender or any further action in response to this extension.

Eli Lilly and Company stock overview

Since entering the stock market in 1983, Eli Lilly's stock has done exceptionally well, as the company has managed to generate 11,694 percent growth. Looking at five-year performance alone, the company's stock is up 344 percent. It seems that for the time being, the only way for the company's stock value to go was up, without a significant correction. However, there was also a period when the price went mostly sideways. The current value per share is close to the all-time high, which was $469 per share in June of this year. *


Eli Lilly's stock price movement over the past five years. (Source: Google Finance) *


Eli Lilly has seen good stock market performance thanks in part to constant innovation and new developments, and throughout the company's history it has more or less only gone up, which is a good sign of a stable company. * If Eli Lilly continues on this trend and does not slow down, it could produce positive results that will benefit it in the future.1 However, we all know how unpredictable the markets are, so it is important to approach stock purchases with the utmost caution, even though it may seem like a solid decision to do so.


Olivia Lacenova, Principal Analyst at Wonderinterest Trading Ltd.


* Past performance is no guarantee of future results

[1,] Forward-looking statements are based on assumptions and current expectations, which may be inaccurate or based on the current economic environment, which may change. Such statements are not guarantees of future results. They involve risks and other uncertainties that are difficult to predict. Results may differ materially from those expressed or implied by any forward-looking statements.


This text constitutes marketing communication. It is not any form of investment advice or investment research or an offer for any transactions in financial instrument. Its content does not take into consideration individual circumstances of the readers, their experience or financial situation. The past performance is not a guarantee or prediction of future results.

🍪 Cookies

We use cookies to store, access and process personal data to give you the best online experience. By clicking Accept Cookies you consent to storing all cookies and ensure best website performance. You can modify cookie preferences or withdraw consent by clicking Cookie Settings. To find out more about cookies and purposes, read our Cookie Policy and Privacy Notice.

Cookies settings

Cookie Control

What are cookies?

Cookies are small text files that enable us, and our service provides to uniquely identify your browser or device. Cookies normally work by assigning a unique number to your device and are stored on your browser by the websites that you visit as well as third-party service providers for those website. By the term cookies other technologies as SDKs, pixels and local storage are to be considered.

If Enabled

We may recognize you as a customer which enables customized services, content and advertising, services effectiveness and device recognition for enhanced security
We may improve your experience based on your previous session
We can keep track of your preferences and personalize services
We can improve the performance of Website.

If Disabled

We won't be able to remember your previous sessions, that won't allow us to tailor the website according to your preferences
Some features might not be available and user experience reduced without cookies

Strictly necessary means that essential functions of the Website can not be provided without using them. Because these cookies are essential for the properly working and secure of Website features and services, you cannot opt-out of using these technologies. You can still block them within your browser, but it might cause the disfunction of basic website features.

  • Setting privacy preferences
  • Secure log in
  • Secure connection during the usage of services
  • Filling forms

Analytics and performance tracking technologies to analyze how you use the Website.

  • Most viewed pages
  • Interaction with content
  • Error analysis
  • Testing and Measuring various design effectivity

The Website may use third-party advertising and marketing technologies.

  • Promote our services on other platforms and websites
  • Measure the effectiveness of our campaigns

Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 57.50% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.